BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 06, 2023 06:00 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
March 03, 2023 14:07 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO...
IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
December 13, 2022 08:17 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
BiondVax Regains Nasdaq Compliance
December 12, 2022 07:06 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
December 06, 2022 08:30 ET
|
BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
December 06, 2022 07:30 ET
|
BiondVax Pharmaceuticals Ltd.
Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
November 30, 2022 09:15 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative...
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
November 29, 2022 07:00 ET
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
November 15, 2022 08:33 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
BiondVax Announces Plan to Implement ADS Ratio Change
November 10, 2022 16:00 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...